Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 17/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 15/20 | 0.81 |
| ▸ | MBTD1 | Q05BQ5 | 7/20 | 0.70 |
| ▸ | L3MBTL4 | Q8NA19 | 3/20 | 0.68 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24185620 | 0.99 | L3MBTL3 (0.83) | L3MBTL3L3MBTL1MBTD1L3MBTL4TP53BP1 | |
| SCHEMBL24185621 | 0.99 | L3MBTL3 (0.83) | L3MBTL3L3MBTL1MBTD1L3MBTL4TP53BP1 | |
| SCHEMBL24185224 | 0.99 | L3MBTL3 (0.83) | L3MBTL3L3MBTL1MBTD1L3MBTL4TP53BP1 | |
| SCHEMBL23682705 | 0.90 | L3MBTL3 (1.00) | L3MBTL3L3MBTL1MBTD1L3MBTL4TP53BP1 | |
| SCHEMBL6843143 | 0.90 | L3MBTL3 (0.73) | L3MBTL3L3MBTL1MBTD1L3MBTL4TP53BP1 | |
| SCHEMBL1448727 | 0.86 | L3MBTL3 (0.78) | L3MBTL3L3MBTL1MBTD1L3MBTL4TP53BP1 | |
| SCHEMBL1449079 | 0.84 | L3MBTL3 (0.81) | L3MBTL3L3MBTL1MBTD1L3MBTL4TP53BP1 | |
| SCHEMBL1735171 | 0.84 | L3MBTL1 (0.81) | L3MBTL3L3MBTL1MBTD1L3MBTL4TP53BP1 | |
| SCHEMBL1449083 | 0.84 | L3MBTL3 (0.81) | L3MBTL3L3MBTL1MBTD1L3MBTL4TP53BP1 | |
| SCHEMBL13024627 | 0.84 | L3MBTL1 (0.81) | L3MBTL3L3MBTL1MBTD1L3MBTL4TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301928-A1 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | CCNI, MKI67, TYMP | L3MBTL3 3141/4885L3MBTL1 2832/4885MBTD1 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.